TCM
YMAB

Tuttle Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Tuttle Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-11,618
Closed -$309K – 254
2019
Q3 		$309K Buy
+11,618
New +$297K 0.08% 198

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Tuttle Capital Management's YMAB Position: Q4 2019 in Review

Tuttle Capital Management sold out of Y-mAbs Therapeutics (YMAB) in Q4 2019, closing a stake of 11,618 shares — an estimated $309K sold.

Tuttle Capital Management first reported a position in YMAB in Q3 2019 and held it in 1 quarter. The position peaked at $309K in Q3 2019. 81 funds tracked by Wall St. Rank hold YMAB as of Q4 2019.

  • Tuttle Capital Management reported no remaining Y-mAbs Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Tuttle Capital Management sold 11,618 Y-mAbs Therapeutics shares in Q4 2019, an estimated $309K.
  • Tuttle Capital Management first reported a position in Y-mAbs Therapeutics in Q3 2019 and held it in 1 quarter.
  • Tuttle Capital Management's Y-mAbs Therapeutics position peaked at $309K in Q3 2019.
  • 81 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2019.

Based on Tuttle Capital Management's 13F filing for Q4 2019, filed 13 Jan 2020.